BACK TO FAESFARMA.COM
Investor's agenda
Upcoming events
Publication of first half-year results

July 24, 2025

All events
2023 Results publication

February 27, 2024

Payment of interim dividend for 2023 at the rate of 0.039 euros per share

January 15, 2024

Annual General Meeting 2023

June 15, 2023

Scrip dividend 2022

April 12 to 26, 2023

Payment of interim dividend for 2022 at the rate of 0.037 euros per share

January 9, 2023

Payment of the supplementary 2021 dividend of Euros 0.035 euros

June 30, 2022

Newsletter

Subscribe to our newsletter

Welcome to our Investor’s corner, the FAES FARMA mailing list. If you want to be the first to find out about the most significant information affecting our company, please sign up by completing the following form.

    First Name *
    Last Name *
    Company
    ID Number
    Email *

    Privacy Policy

    Pursuant to the Organic Law on Data Protection of 15/1999 of 13 December, we inform you that the data you submit will now form part of a file owned by FAES FARMA S.A., for the purpose of keeping you informed about our company’s products and the activities we carry out.

    Accept

    Responsible FAES FARMA, S.A.+info
    Purpose To maintain the contact and communication with shareholders+info
    Legal capacity Consent from the user+info
    Recipients Responsibles for data treatment within the EU +info
    Rights Access, rectify and suppress data, as well as other rights, as explained in the further information field+info
    Origin The interested party themself +info
    Further information You can check further information detailed about Data Protection within our website: privacy policy

    Investor's corner
    Shareholders and Investors Contact

    As part of its commitment to transparency and rigorous information, FAES FARMA has established this section for our shareholders and investors. Here, we provide all the required information, as well as any other details the Company deems relevant regarding Corporate Governance practices.

    We have an email address and phone number for providing an effective service to everybody who has placed their trust in our company.

    Shareholders Contact

    accionistas@faesfarma.com

    Tel.: (+34) 900 922 554

    Avda. Autonomía, 10. 48940 Leoia (Vizcaya)

    Tel.: (+34) 94 481 83 00

    News
    Financial Reporting
    Go to News
    Economic and Financial News
    September 2nd, 2025

    Faes Farma completes the acquisition of SIFI and consolidates its international leadership in ophthalmology

    The transaction reinforces the Group’s new global strategy and boosts ophthalmology as one of its key growth areas. Thanks to this transaction and the acquisition of Edol in March, ophthalmology will account […]

    Economic and Financial News
    July 24th, 2025

    Faes Farma increases revenue by 12.3% to €307.4 million

    The pharmaceutical business grew by +9% to €269 million, with international markets (+14%) and licenses (+13%) continuing to be the main drivers of growth. The three strategic molecules (Bilastine, Calcifediol and Mesalazine) […]

    Economic and Financial News
    July 16th, 2025

    Faes Farma’s Shareholders’ Meeting approves the acquisition of 100% of SIFI

    Shareholder support consolidates the transaction as a transformational step for the company’s strategy The acquisition consolidates Faes Farma as a leading ophthalmology company with one of the most comprehensive offerings in the […]

    Economic and Financial News
    June 25th, 2025

    Faes Farma reaffirms its ambition and strategic plan to 2030 to its shareholders

    The Meeting approves the payment of a final dividend of 0.138 euros per share on July 7, for a total dividend of 0.179 euros per share, a pay-out of 51%. All items […]

    Economic and Financial News
    June 10th, 2025

    Faes Farma Acquires SIFI: A Transformational Step Aligned With 2030 Ambitions and Strategy

    This acquisition consolidates Faes Farma as a leader in ophthalmology, incorporating a broad portfolio in this key therapeutic area. It enhances the Group’s international expansion, facilitating direct entry into new European markets. […]

    Economic and Financial News
    March 25th, 2025

    Faes Farma signs an agreement to acquire Laboratorios Edol, a leader in ophthalmology in Portugal

    Ophthalmology represents a key strategic opportunity for Faes Farma as it is a therapeutic area with expected double-digit growth. This milestone reinforces Faes Farma’s international growth strategy and consolidates its position in […]